Abstract
This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well known anti-neoplastic drug, methotrexate (MTX) and its comparison to ‘AChE-cyclophosphamide (CP) interactions’ that we reported previously. Docking between MTX and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of MTX within the ‘acyl pocket’ as well as ‘catalytic site’ of AChE to permit docking. However, docking of CP to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of MTX. Scope still remains in the determination of the three-dimensional structure of AChE-MTX complex by X-ray crystallography to validate the described data. The current computational study supports our previous experimental study which concluded a mixed inhibition model for AChE-inhibition by MTX. Furthermore, the present report confirms that MTX is a more efficient inhibitor of human brain AChE compared to CP with reference to Ki and ΔG values.
Keywords: Methotrexate, Docking, Enzyme-Inhibition, Human Brain Acetylcholinestrase, MTX, CTX-M-15, Cephalosporin, Cefotaxime, AChE, Desolvation, Cyclophosphamide, Galantamine
CNS & Neurological Disorders - Drug Targets
Title:Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study
Volume: 11 Issue: 2
Author(s): Shazi Shakil, Mohammad A. Kamal, Shams Tabrez, Adel M. Abuzenadah, Adeel G.A. Chaudhary, Ghazi A. Damanhouri
Affiliation:
Keywords: Methotrexate, Docking, Enzyme-Inhibition, Human Brain Acetylcholinestrase, MTX, CTX-M-15, Cephalosporin, Cefotaxime, AChE, Desolvation, Cyclophosphamide, Galantamine
Abstract: This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well known anti-neoplastic drug, methotrexate (MTX) and its comparison to ‘AChE-cyclophosphamide (CP) interactions’ that we reported previously. Docking between MTX and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of MTX within the ‘acyl pocket’ as well as ‘catalytic site’ of AChE to permit docking. However, docking of CP to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of MTX. Scope still remains in the determination of the three-dimensional structure of AChE-MTX complex by X-ray crystallography to validate the described data. The current computational study supports our previous experimental study which concluded a mixed inhibition model for AChE-inhibition by MTX. Furthermore, the present report confirms that MTX is a more efficient inhibitor of human brain AChE compared to CP with reference to Ki and ΔG values.
Export Options
About this article
Cite this article as:
Shazi Shakil, Mohammad A. Kamal, Shams Tabrez, Adel M. Abuzenadah, Adeel G.A. Chaudhary, Ghazi A. Damanhouri , Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study, CNS & Neurological Disorders - Drug Targets 2012; 11 (2) . https://dx.doi.org/10.2174/187152712800269669
DOI https://dx.doi.org/10.2174/187152712800269669 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Current Drug Safety Neurohormonal Activation in Ischemic Stroke: Effects of Acute Phase Disturbances on Long-Term Mortality
Current Neurovascular Research Non-Pharmacological Interventions to Improve Health Status in COPD
Current Respiratory Medicine Reviews Modulating the Amyloidogenesis of α-Synuclein
Current Neuropharmacology Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Current Alzheimer Research Patents in the Diagnosis and Therapy of Neurocardiogenic Syncope
Recent Patents on Cardiovascular Drug Discovery Using Functional Neuroimaging to Investigate the Mechanisms of Action of Selective Serotonin Reuptake Inhibitors (SSRIs)
Current Pharmaceutical Design Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment
Current Alzheimer Research Alcohol Addiction- Metabotropic Glutamate Receptor Subtype 5 and its Ligands: How They All Come Together?
Current Drug Targets Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Anticonvulsants – Antidepressants Pharmacokinetic Drug Interactions: The Role of the CYP450 System in Psychopharmacology
Current Drug Metabolism A Dual Targeting Drug Delivery System for Penetrating Blood-Brain Barrier and Selectively Delivering siRNA to Neurons for Alzheimer’s Disease Treatment
Current Pharmaceutical Biotechnology Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach
Current Alzheimer Research Cognitive Impairment in Depression
Current Psychiatry Reviews Role of Oxygen Radicals on Bronchial Asthma
Current Drug Targets - Inflammation & Allergy